Medidur for non-infectious posterior uveitis – second line

NIHR HSRIC
Record ID 32016000813
English
Authors' recommendations: Uveitis is an inflammation that affects the lining of the eye. It can lead to eye pain, eye redness, headaches, and problems with vision that can become permanent. It may be caused by an infection, but in many cases the cause of uveitis is unknown. Medidur is a new drug implant that is injected straight into the back of the eye. It releases a corticosteroid drug called fluocinolone acetonide for as long as 3 years. Corticosteroids are already used to treat uveitis, but need to be taken daily as tablets or injected into the eye on regular occasions. If Medidur is licensed for use in the UK, it could be a new treatment option for patients with uveitis. It could be particularly helpful for patients who are not responding to standard drug treatments and to try to reduce the risk of the disease returning.
Details
Project Status: Completed
Year Published: 2016
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Intravitreal Injections
  • Uveitis, Posterior
  • Adrenal Cortex Hormones
  • Drug Implants
  • Eye Pain
Contact
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name: c.packer@bham.ac.uk
Contact Email: c.packer@bham.ac.uk
Copyright: NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.